桥接治疗对大B细胞淋巴瘤CD19 CAR-T治疗的影响
In the relapsed/refractory setting for treatment of large B-cell lymphoma (LBCL), chimeric antigen receptor T-cell (CAR-T) therapy has emerged as an effective treatment modality.…
要点
- 全身性或放疗桥接者第180天血细胞减少风险高于激素桥接或未桥接者。
核心结论
- 桥接治疗可安全用于接受CAR-T治疗的大B细胞淋巴瘤患者,但全身性或放疗桥接者CAR-T后持续性血细胞减少风险更高。
主要发现
- 桥接治疗组、未桥接组及各桥接亚组在末次随访时的疾病缓解、无进展生存期和总生存期相似。
关键数值与推荐
- 桥接治疗方式包括全身性桥接28例、放疗桥接14例、大剂量激素桥接10例。
临床怎么用
- 对于需要桥接治疗的大B细胞淋巴瘤患者,可考虑桥接治疗以稳定病情,但应警惕全身性或放疗桥接后持续性血细胞减少的风险。
局限性
- 本研究为单中心回顾性分析,样本量较小(n=75),结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In the relapsed/refractory setting for treatment of large B-cell lymphoma (LBCL), chimeric antigen receptor T-cell (CAR-T) therapy has emerged as an effective treatment modality. Patients often have aggressive disease that requires prompt treatment in the form of bridging therapy (BT) for disease stabilisation while CAR-T cells are manufactured. Patients (n = 75) undergoing CAR-T therapy infusion for LBCL at our institution were identified. A total of 52 (69·3%) received BT and 23 (30·7%) received no BT (NBT). BT modalities included systemic BT (SBT) in 28 patients, radiation BT (RBT) in 14, and high-dose steroid BT (HDS) in 10. There was no difference in incidence of cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome between BT and NBT (P = 0·18 and P = 0·53 respectively). Prolonged cytopenias at Day 180 were more common in BT than NBT (50% vs. 13·3%, P = 0·04). The SBT and RBT subgroups had more cytopenias at Day 180 compared to the HDS and NBT subgroups (58·3% and 57·1% vs. 20% and 13·3% respectively, P = 0·04). Disease response at last follow-up, progression-free survival and overall survival were similar between BT, NBT, and BT subgroups. In summary, BT can be safely considered in patients undergoing CAR-T therapy. However, those undergoing BT with SBT or RBT are at higher risk of prolonged cytopenias after CAR-T therapy.
引用
- Lutfi F, Holtzman NG, Kansagra AJ, et al. The impact of bridging therapy prior to CD19-directed chimeric antigen receptor T-cell therapy in patients with large B-cell lymphoma. Br J Haematol. 2021. PMID: 34500492. doi:10.1111/bjh.17738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。